Sanofi reaches licensing deal with Wellstat for diabetes drug

10/21/2009 | Reuters

Sanofi-Aventis has acquired worldwide licensing rights to Wellstat Therapeutics' diabetes drug PN2034 in a deal worth up to $350 million. The product, which is in Phase II trials, is an oral "insulin sensitizer" that improves insulin action in the livers of patients with Type 2 diabetes.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX